M
MBrace Therapeutics
REACHING TO IMPROVE THE LIVES OF
About MBrace Therapeutics
MBrace is a healthcare startup that focuses on developing innovative treatments for cancer patients. The company's primary technology, known as SPARTA, is a robust antibody discovery methodology that helps to overcome challenges in generating human antibodies for clinical applications. This technology is used to develop Antibody-Drug Conjugates (ADCs), a type of targeted therapy that delivers cancer-killing drugs directly to cancer cells, against two novel cancer targets.
MBrace's business model revolves around the research, development, and commercialization of these new treatments. The company's primary clients are cancer patients who are in need of more effective and targeted treatment options. The company operates in the biotechnology and healthcare market, a sector that is continually growing due to the increasing prevalence of various types of cancer and the ongoing need for more effective treatments.
The company also collects and uses data from various sources, including information provided by individuals for job applications or inquiries. This data is used for a variety of purposes, including analytics and improving the company's services. MBrace also discloses deidentified and aggregated information about its users without restriction, which could potentially provide additional revenue streams.
In summary, MBrace is a biotech startup that uses its proprietary SPARTA technology to develop targeted cancer treatments. The company operates in the healthcare market, serving cancer patients and using collected data to improve its services and potentially generate additional revenue.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Nov 2023 | $85M | $340M | TPG · Venrock · Alta Partners · Avidity Partners | ↗ |
| SERIES AOther financing | Jan 2021 | $25M | $100M | Venrock · Alta Partners | ↗ |
Growth signals
Latest recorded traffic for MBrace Therapeutics is 3.9K monthly website visits, down 11.4% over the last three months. MBrace Therapeutics's team grew 8.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
MBrace Therapeutics in the San Diego ecosystem
The MBrace Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MBrace Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MBrace Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.














